AI Meets Cell Therapy Manufacturing

During this segment of Cell & Gene Live, "Building Smarter Cell Therapies with AI and Synthetic Biology," Senti Biosciences' Tim Lu, M.D., Ph.D., and Claire Aldridge, Ph.D., advised regulators and partners view AI/circuit-engineered cell therapies with healthy skepticism, reassured by evidence of acceleration (not replacement) of wet lab steps with robust validation data. They stressed that strong infrastructure signals include openness to tech optimization, data driven manufacturing scores, and tools to predict yield issues from payload design, helping lower COGS while ensuring safety matches the indication’s risk profile.